Myeloproliferative Neoplasms (MPN)

A decade after the discovery of CALR, the results are the first for a possible therapy for CALR-mutated MPNs to reach the clinic.

The key driver in both sets of findings is the relationship between neutrophils and inflammation.

Authors found the pharmacy costs for momelotinib were $11,095 higher per month, too much to offset higher transfusion costs for ruxolitinib.

Being married and having insurance can offer emotional support and financial stability to lead to early diagnosis and effective treatment, the authors found.

Experts are asking whether the study and treatment of myeloproliferative neoplasms (MPNs) is ready for a new era with new end points, with data that show how survival benefits are biologically linked to changes in the spleen, reduction in fibrosis, or other responses.

There can be a delay in diagnosis of myeloproliferative neoplasms as the symptoms of the diseases can be variable and common, such as fatigue, migraines, and difficulty concentrating, explained Ruben Mesa, MD, of Atrium Health.

Investigators added more data to an analysis first published in 2020 and got the same result: ruxolitinib beats other treatments for polycythemia vera.

An August 2024 update to the National Comprehensive Cancer Network (NCCN) clinical practice guidelines for treatment of myeloproliferative neoplasms (MPN) calls puts a priority on clinical trials, even preferring them to FDA-approved therapies in some cases. Aaron Gerds, MD, MS, of Cleveland Clinic Taussig Cancer Institute discusses the updates and what's in the pipeline for MPN treatment.

A study based on a decade's worth of Korean insurance data found that use of direct oral anticoagulants (DOACs) to address atrial fibrillation and venous thromboembolism in patients with myeloproliferative neoplasms (MPNs) is effective, with acceptable bleeding risk.

Researchers from Bulgaria conduct an analysis of the potential for therapeutic vaccines in by comparing testing results for patients from their country with an international data set.

Inflammation and genetic mutations can drive cardiovascular complications in patients with myeloproliferative neoplasms, which include disorders such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis.

A review by authors from China examines evidence involving different treatment approaches.

While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).

The introduction of momelotinib to treat myelofibrosis with anemia can result in small savings due to reduced transfusion-related costs, according to a budget impact model.

Differing characteristics of the patient and their disease may mean certain providers—academic oncologists, community oncologists, and primary care physicians—may be best suited for follow-up care.

For most patients younger than age 60 with polycythemia vera (PV) who are not considered high risk, cytoreductive therapies are withheld despite being highly effective.

Despite potential benefits, the therapy remains in limited use for myeloproliferative neoplasms (MPNs).

New research highlights the factors that increase the likelihood that essential thrombocytopenia (ET), polycythemia vera (PV), and prefibrotic primary myelofibrosis (PrePMF) will evolve into overt myelofibrosis (MF).

Compared with matched controls, patients with myeloproliferative neoplasms (MPNs) had a higher risk of developing thrombosis, hemorrhage, and leukemic transformation, according to a longitudinal cohort study.

A review of research confirms that adolescents and young adults (AYA) with myeloproliferative neoplasms (MPN) face psychological burdens but the exact burden is poorly understood.

The National Comprehensive Cancer Network (NCCN) recommends ropeginterferon alfa-2b as first-line cytoreductive therapy for polycythemia vera.

Polycythemia vera (PV) therapy should aim to identify cardiovascular risk factors, according to one review.

A phase 3 trial in symptomatic and anemic patients with myelofibrosis (MF) met its primary end point, seeing a significant symptom reduction at 24 weeks with momelotinib vs danazol.

Researchers identified distinct patterns of epigenetic dysregulation in myeloproliferative neoplasms.

Budd-Chiari syndrome and myeloproliferative neoplasms (MPNs) are rare, which means available data are limited.